Nothing Special   »   [go: up one dir, main page]

MX2021001524A - Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso. - Google Patents

Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.

Info

Publication number
MX2021001524A
MX2021001524A MX2021001524A MX2021001524A MX2021001524A MX 2021001524 A MX2021001524 A MX 2021001524A MX 2021001524 A MX2021001524 A MX 2021001524A MX 2021001524 A MX2021001524 A MX 2021001524A MX 2021001524 A MX2021001524 A MX 2021001524A
Authority
MX
Mexico
Prior art keywords
specific binding
binding proteins
cancer
nkg2d
methods
Prior art date
Application number
MX2021001524A
Other languages
English (en)
Inventor
Asya Grinberg
Bianka Prinz
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Nicolai Wagtmann
Mitchell Bigelow
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2021001524A publication Critical patent/MX2021001524A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen proteínas de unión multiespecíficas que se unen y matan células cancerosas humanas, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer. El cáncer puede ser un cáncer que expresa el antígeno de maduración de linfocitos B (BCMA). Las proteínas de unión multiespecíficas proporcionadas en la presente exhiben alta potencia y lisis máxima de células objetivo en comparación con anticuerpos monoclonales anti-BCMA.
MX2021001524A 2018-08-08 2019-08-08 Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso. MX2021001524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716207P 2018-08-08 2018-08-08
PCT/US2019/045632 WO2020033630A1 (en) 2018-08-08 2019-08-08 Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use

Publications (1)

Publication Number Publication Date
MX2021001524A true MX2021001524A (es) 2021-04-19

Family

ID=69413838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001524A MX2021001524A (es) 2018-08-08 2019-08-08 Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.

Country Status (19)

Country Link
US (2) US20210317223A1 (es)
EP (1) EP3833392A4 (es)
JP (1) JP7515459B2 (es)
KR (1) KR20210043602A (es)
CN (1) CN112823022A (es)
AR (1) AR114544A1 (es)
AU (1) AU2019318083A1 (es)
BR (1) BR112021002072A2 (es)
CA (1) CA3108427A1 (es)
CL (1) CL2021000316A1 (es)
CO (1) CO2021001410A2 (es)
EA (1) EA202190468A1 (es)
IL (1) IL280512A (es)
MA (1) MA53293A (es)
MX (1) MX2021001524A (es)
PE (1) PE20211860A1 (es)
SG (1) SG11202100883SA (es)
TW (1) TW202019479A (es)
WO (1) WO2020033630A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CA3191282A1 (en) * 2020-09-11 2022-03-17 William Pierceall Combination therapy for cancer
WO2023011431A1 (zh) * 2021-08-03 2023-02-09 江苏先声药业有限公司 一种cd16抗体及其应用
US20230203202A1 (en) * 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
CN103328514B (zh) * 2010-11-09 2015-12-02 阿尔蒂单抗治疗公司 用于抗原结合的蛋白复合物及其使用方法
EP4338754A3 (en) 2011-05-27 2024-07-10 Glaxo Group Limited Antigen binding proteins
US20140377269A1 (en) * 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
ES2750725T3 (es) 2014-12-12 2020-03-26 Bluebird Bio Inc Receptores de antígeno quiméricos BCMA
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
JP2018510623A (ja) * 2015-02-20 2018-04-19 オハイオ・ステイト・イノベーション・ファウンデーション Ｎｋｇ２ｄ及び腫瘍関連抗原に対する二価抗体
EA201792226A1 (ru) * 2015-04-06 2018-08-31 САБДОМЭН, ЭлЭлСи Полипептиды, содержащие de novo связывающий домен, и их применение
DK3331910T3 (da) 2015-08-03 2020-03-16 Engmab Sarl Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma)
ES2814550T3 (es) 2015-08-17 2021-03-29 Janssen Pharmaceutica Nv Anticuerpos anti-BCMA, moléculas que se unen a antígeno biespecífico que se unen a BCMA y CD3, y usos de los mismos
CN109153728A (zh) * 2016-03-21 2019-01-04 埃尔斯塔治疗公司 多特异性和多功能分子及其用途
EP3544996A2 (en) * 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR20190115469A (ko) * 2017-02-10 2019-10-11 드래곤플라이 쎄라퓨틱스, 인크. Bcma, nkg2d 및 cd16에 결합하는 단백질

Also Published As

Publication number Publication date
PE20211860A1 (es) 2021-09-21
CN112823022A (zh) 2021-05-18
US20210317223A1 (en) 2021-10-14
BR112021002072A2 (pt) 2021-06-01
IL280512A (en) 2021-03-25
SG11202100883SA (en) 2021-02-25
KR20210043602A (ko) 2021-04-21
WO2020033630A1 (en) 2020-02-13
AU2019318083A1 (en) 2021-02-25
CL2021000316A1 (es) 2021-07-30
CA3108427A1 (en) 2020-02-13
JP7515459B2 (ja) 2024-07-12
US20220089760A1 (en) 2022-03-24
EP3833392A1 (en) 2021-06-16
MA53293A (fr) 2021-11-17
EP3833392A4 (en) 2022-05-18
JP2021533169A (ja) 2021-12-02
CO2021001410A2 (es) 2021-05-10
EA202190468A1 (ru) 2021-07-06
TW202019479A (zh) 2020-06-01
AR114544A1 (es) 2020-09-16

Similar Documents

Publication Publication Date Title
MX2020008684A (es) Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
JOP20200309A1 (ar) أجسام مضادة لـ il-11
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
PH12020552229A1 (en) Il-11ra antibodies
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
MX2019013998A (es) Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2019015477A (es) Proteinas de union a antigeno del virus del papiloma anti-humano (vph) y metodos de uso de las mismas.
CR20200463A (es) Anticuerpos
MX2020002036A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor.
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
MX2022004430A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
MX2019013995A (es) Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.
MX2020012273A (es) Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.